Miguel Foronda

Miguel Foronda

Auto-generated profile, based on publicly available information

Miguel Foronda

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York. 6

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
ARAndrew J Ramsay
Andrew J Ramsay
VQVíctor Quesada
Víctor Quesada
MFMiguel Foronda
Miguel Foronda
LCLaura Conde
Laura Conde
AMAlejandra Martínez-Trillos
Alejandra Martínez-Trillos
CLCarlos López-Otín
Carlos López-Otín

1 October 2012 in Cell Reports
Verified
Journal Article
Open access
EVElsa Vera
Elsa Vera
BJBruno Bernardes de Jesus
Bruno Bernardes de Jesus
MFMiguel Foronda
Miguel Foronda
JFJuana M. Flores
Juana M. Flores
MBMaria A. Blasco
Maria A. Blasco
Aberrantly short telomeres result in decreased longevity in both humans and mice with defective telomere maintenance. Normal populations of humans and mice present high interindividual variation in telomere length, but it is unknown whether this is associated with their lifespan potential. To address this issue, we performed a longitudinal telomere length study along the lifespan of wild-type and transgenic telomerase reverse transcriptase mice. We found that mouse telomeres shorten ∼100 times faster than human telomeres. Importantly, the rate of increase in the percentage of short telomeres, rather than the rate of telomere shortening per month, was a significant predictor of lifespan in both mouse cohorts, and those individuals who showed a higher rate of increase in the percentage of short telomeres were also the ones with a shorter lifespan. These findings demonstrate that short telomeres have a direct impact on longevity in mammals, and they highlight the importance of performing longitudinal telomere studies to predict longevity.

15 December 2010 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
RSRaffaele Strippoli
Raffaele Strippoli
IBIgnacio Benedicto
Ignacio Benedicto
MFMiguel Foronda
Miguel Foronda
MLMaria-Luisa Pérez Lozano
Maria-Luisa Pérez Lozano
SSSara Sánchez-Perales
Sara Sánchez-Perales
MPMiguel A. del Pozo
Miguel A. del Pozo
Epithelial-to-mesenchymal transition (EMT) of peritoneal mesothelial cells is a pathological process that occurs during peritoneal dialysis. EMT leads to peritoneal fibrosis, ultrafiltration failure and eventually to the discontinuation of therapy. Signaling pathways involved in mesothelial EMT are thus of great interest, but are mostly unknown. We used primary mesothelial cells from human omentum to analyze the role of the p38 MAPK signaling pathway in the induction of EMT. The use of specific inhibitors, a dominant-negative p38 mutant and lentiviral silencing of p38α demonstrated that p38 promotes E-cadherin expression both in untreated cells and in cells co-stimulated with the EMT-inducing stimuli transforming growth factor (TGF)-β1 and interleukin (IL)-1β. p38 inhibition also led to disorganization and downregulation of cytokeratin filaments and zonula occludens (ZO)-1, whereas expression of vimentin was increased. Analysis of transcription factors that repress E-cadherin expression showed that p38 blockade inhibited expression of Snail1 while increasing expression of Twist. Nuclear translocation and transcriptional activity of p65 NF-κB, an important inducer of EMT, was increased by p38 inhibition. Moreover, p38 inhibition increased the phosphorylation of TGF-β-activated kinase 1 (TAK1), NF-κB and IκBα. The effect of p38 inhibition on E-cadherin expression was rescued by modulating the TAK1–NF-κB pathway. Our results demonstrate that p38 maintains E-cadherin expression by suppressing TAK1–NF-κB signaling, thus impeding the induction of EMT in human primary mesothelial cells. This represents a novel role of p38 as a brake or ‘gatekeeper’ of EMT induction by maintaining E-cadherin levels.

22 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EVElsa Vera
Elsa Vera
BJBruno Bernardes de Jesus
Bruno Bernardes de Jesus
MFMiguel Foronda
Miguel Foronda
JFJuana M. Flores
Juana M. Flores
MBMaria A. Blasco
Maria A. Blasco
Caloric restriction (CR), a reduction of food intake while avoiding malnutrition, can delay the onset of cancer and age-related diseases in several species, including mice. In addition, depending of the genetic background, CR can also increase or decrease mouse longevity. This has highlighted the importance of identifying the molecular pathways that interplay with CR in modulating longevity. Significant lifespan extension in mice has been recently achieved through over-expression of the catalytic subunit of mouse telomerase (mTERT) in a cancer protective background. Given the CR cancer-protective effects in rodents, we set to address here whether CR impacts on telomere length and synergizes with mTERT to extend mouse longevity. CR significantly decreased tumor incidence in TERT transgenic (TgTERT) mice and extended their lifespan compared to wild-type (WT) controls under the same diet, indicating a synergy between TgTERT and CR in increasing mouse longevity. In addition, longitudinal telomere length measurements in peripheral blood leukocytes from individual mice showed that CR resulted in maintenance and/or elongation telomeres in a percentage of WT mice, a situation that mimics telomere dynamics in TgTERT cohorts. These results demonstrate that CR attenuates telomere erosion associated to aging and that synergizes with TERT over-expression in increasing “health span” and extending mouse longevity.

1 October 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ESEmma M. Schatoff
Emma M. Schatoff
SGSukanya Goswami
Sukanya Goswami
MZMaria Paz Zafra
Maria Paz Zafra
MFMiguel Foronda
Miguel Foronda
MSMichael Shusterman
Michael Shusterman
LDLukas E. Dow
Lukas E. Dow
The majority of colorectal cancers show hyperactivated WNT signaling due to inactivating mutations in the adenomatous polyposis coli (APC) tumor suppressor. Genetically restoring APC suppresses WNT and induces rapid and sustained tumor regression, implying that reengaging this endogenous tumor-suppressive mechanism may be an effective therapeutic strategy. Here, using new animal models, human cell lines, and ex vivo organoid cultures, we show that tankyrase (TNKS) inhibition can control WNT hyperactivation and provide long-term tumor control in vivo, but that effective responses are critically dependent on how APC is disrupted. Mutant APC proteins truncated within the mutation cluster region physically engage the destruction complex and suppress the WNT transcriptional program, while APC variants with early truncations (e.g., ApcMin) show limited interaction with AXIN1 and β-catenin, and do not respond to TNKS blockade. Together, this work shows that TNKS inhibition, like APC restoration, can reestablish endogenous control of WNT/β-catenin signaling, but that APC genotype is a crucial determinant of this response. Significance: This study reveals how subtle changes to the mutations in a critical colorectal tumor suppressor, APC, influence the cellular response to a targeted therapy. It underscores how investigating the specific genetic alterations that occur in human cancer can identify important biological mechanisms of drug response and resistance. This article is highlighted in the In This Issue feature, p. 1325

30 December 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
RSRaffaele Strippoli
Raffaele Strippoli
JLJesús Loureiro
Jesús Loureiro
VMVanessa Moreno
Vanessa Moreno
IBIgnacio Benedicto
Ignacio Benedicto
MLMaria-Luisa Pérez Lozano
Maria-Luisa Pérez Lozano
MPMiguel A. del Pozo
Miguel A. del Pozo
Peritoneal dialysis (PD) is a form of renal replacement therapy whose repeated use can alter dialytic function through induction of epithelial–mesenchymal transition (EMT) and fibrosis, eventually leading to PD discontinuation. The peritoneum from Cav1 −/− mice showed increased EMT, thickness, and fibrosis. Exposure of Cav1 −/− mice to PD fluids further increased peritoneal membrane thickness, altered permeability, and increased the number of FSP‐1/cytokeratin‐positive cells invading the sub‐mesothelial stroma. High‐throughput quantitative proteomics revealed increased abundance of collagens, FN, and laminin, as well as proteins related to TGF‐β activity in matrices derived from Cav1 −/− cells. Lack of Cav1 was associated with hyperactivation of a MEK‐ERK1/2‐Snail‐1 pathway that regulated the Smad2‐3/Smad1‐5‐8 balance. Pharmacological blockade of MEK rescued E‐cadherin and ZO‐1 inter‐cellular junction localization, reduced fibrosis, and restored peritoneal function in Cav1 −/− mice. Moreover, treatment of human PD‐patient‐derived MCs with drugs increasing Cav1 levels, as well as ectopic Cav1 expression, induced re‐acquisition of epithelial features. This study demonstrates a pivotal role of Cav1 in the balance of epithelial versus mesenchymal state and suggests targets for the prevention of fibrosis during PD.